- Diurnal said it remained on track to file a new drug application for its adrenal drug in the US and an application to market its paediatric adrenal drug in the EU.

The company also said discussions with US partners around its late-stage cortisol deficiency pipeline continued to advance, with a licensing deal expected to conclude during the first half of 2020.

The commercial roll-out of Alkindi, its paediatric adrenal drug, in Europe continued to progress, with sales for the year to date in line with expectations, Diurnal said.

Two regulatory filings were already made for Alkindi during 2019 by its partners Medison and Emerge in Israel and Australia, respectively, Diurnal added.

At 9:24am: [LON:DNL] Diurnal Group Plc share price was +2p at 33p

Story provided by